Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group

American Journal of Hematology

Volumn 91, Issue 7, 2016, Pages 681-686

  Rotunno, Giada ^a   Pacilli, Annalisa ^a   Artusi, Valentina ^b   Rumi, Elisa ^c,d   Maffioli, Margherita ^e   Delaini, Federica ^f   Brogi, Giada ^a   Fanelli, Tiziana ^a,g   Pancrazzi, Alessandro ^a   Pietra, Daniela ^c   Bernardis, Isabella ^b   Belotti, Clara ^f   Pieri, Lisa ^a   Sant'Antonio, Emanuela ^a   Salmoiraghi, Silvia ^f   Cilloni, Daniela ^h   Rambaldi, Alessandro ^f   Passamonti, Francesco ^e   Barbui, Tiziano ^f   Manfredini, Rossella ^b   Cazzola, Mario ^c   Tagliafico, Enrico ^b   Vannucchi, Alessandro M ^a   Guglielmelli, Paola ^a   more..

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e UNIVERSITY OF INSUBRIA   (Italy)

^f PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^g UNIVERSITY OF SIENA   (Italy)

^h UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; TRANSCRIPTION FACTOR EZH2;

ADULT; AGED; ALLELE; ARTICLE; ASXL1 GENE; CALR GENE; CANCER PROGNOSIS; CHRONIC DISEASE; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC RISK; GENOTYPE; HUMAN; LEUKEMIA FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; MYELOFIBROSIS; OVERALL SURVIVAL; POLYCYTHEMIA VERA; POSTESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS; POSTPOLYCYTHEMIA VERA MYELOFIBROSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SRSF2 GENE; THROMBOCYTHEMIA;

EID: 84973882745     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24377     Document Type: Article

References (38)

1. Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007;31:737–740.
2. Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: A literature review of incidence and risk factors. Blood Cancer J 2015; 5:e366
3. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the international working group for myelofibrosis research and treatment. Leukemia 2008;22:437–438.
4. Verstovsek S, Mesa RA, Gotlib J, et al. The clinical benefit of ruxolitinib across patient subgroups: Analysis of a placebo-controlled, phase III study in patients with myelofibrosis. Br J Haematol 2013.
5. Cervantes F, Vannucchi AM, Kiladjian J-J, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122:4047–4053.
6. Pardanani A, Harrison C, Cortes JE, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial. JAMA Oncol 2015;1:643–651.
7. Komrokji RS, Seymour JF, Roberts AW, et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood 2015;125:2649–2655.
8. Hernandez-Boluda J-C, Pereira A, Gomez M, et al. The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis. Haematologica 2014;99:e55–e57.
9. Guglielmelli P, Biamonte F, Score J, et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 2011;118:5227–5234.
10. Lasho TL, Jimma T, Finke CM, et al. SRSF2 mutations in primary myelofibrosis: Significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood 2012;120:4168–4171.
11. Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR or MPL in primary myelofibrosis. Blood 2014;124:1062–1069.
12. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013;27:1861–1869.
13. Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: An international study of 570 patients. Leukemia 2014;28:1494–1500.
14. Tefferi A, Lasho TL, Finke C, et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: Differences in phenotype and prognostic impact. Leukemia 2014;28:1568–1570.
15. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL mutated or triple-negative myelofibrosis: Clinical, cytogenetic and molecular comparisons. Leukemia 2014;28:1472–1477.
16. Guglielmelli P, Rotunno G, Fanelli T, et al. Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis. Blood Cancer J 2015;2015;e360.
17. Guglielmelli P, Biamonte F, Rotunno G, et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II Study. Blood 2014;123:2157–2160.
18. Guglielmelli P, Lasho TL, Rotunno G, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: An international study of 797 patients. Leukemia 2014;28:1804–1810, 1804
19. Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014;123:2220–2228.
20. Wassie E, Finke C, Gangat N, et al. A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients. Br J Haematol 2015;169:71–76.
21. Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2014;123:1552–1555.
22. Tefferi A, Lasho TL, Tischer A, et al. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood 2014;124:2465–2466.
23. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895–2901.
24. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799–807.
25. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787–798.
26. Vannucchi AM, Kantarjian HM, Kiladjian J-J, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis. Haematologica 2015;100:1139–1145.
27. Cabagnols X, Defour JP, Ugo V, et al. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: Relevance for disease evolution. Leukemia 2015;29:249–252.
28. Pietra D, Rumi E, Ferretti VV, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia 2016; 30:431–438.
29. Marty C, Pecquet C, Nivarthi H, et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood 2016;127:1317–1324.
30. Li B, Xu J, Wang J, et al. Calreticulin mutations in Chinese with primary myelofibrosis. Haematologica 2014;99:1697–1700.
31. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 2008;112:844–847.
32. Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014;123:1544–1551.
33. Elala YC, Lasho TL, Gangat N, et al. Calreticulin (CALR) variant stratified driver mutational status and prognosis in essential thrombocythemia. Am J Hematol 2016.
34. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007;110:840–846.
35. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010;24:1574–1579.
36. Silver RT, Vandris K, Wang YL, et al. JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leuk Res 2011;35:177–182.
37. Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: Clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 2012; 26:475–480.
38. Lasho TL, Gangat N, Finke C, et al. Prognostic interactions between SRSF2, ASXL1, and IDH mutations in primary myelofibrosis and determination of added value to cytogenetic risk stratification and DIPSS-Plus. ASH Annual Meeting Abstracts 2012;120:430.